BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 270 filers reported holding BIO-TECHNE CORP in Q1 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $232,000 | -20.0% | 535 | -4.5% | 0.07% | -16.3% |
| Q4 2021 | $290,000 | +2.5% | 560 | -4.3% | 0.09% | -1.1% |
| Q3 2021 | $283,000 | +0.4% | 585 | 0.0% | 0.09% | +3.6% |
| Q2 2021 | $282,000 | +26.5% | 585 | 0.0% | 0.08% | +18.3% |
| Q1 2021 | $223,000 | -75.5% | 585 | -91.7% | 0.07% | -78.7% |
| Q4 2017 | $912,000 | +7.5% | 7,040 | +0.4% | 0.33% | +16550.0% |
| Q3 2017 | $848,000 | -1.6% | 7,015 | -4.4% | 0.00% | -99.4% |
| Q2 2017 | $862,000 | +13.4% | 7,335 | -1.8% | 0.34% | +10.0% |
| Q1 2017 | $760,000 | -0.9% | 7,473 | +0.2% | 0.31% | -4.9% |
| Q4 2016 | $767,000 | -6.0% | 7,455 | 0.0% | 0.32% | -6.6% |
| Q3 2016 | $816,000 | -20.9% | 7,455 | -18.6% | 0.35% | -19.8% |
| Q2 2016 | $1,032,000 | +19.3% | 9,155 | 0.0% | 0.43% | +17.3% |
| Q1 2016 | $865,000 | +6.3% | 9,155 | +1.3% | 0.37% | +2.8% |
| Q4 2015 | $814,000 | -4.7% | 9,040 | -2.2% | 0.36% | -9.1% |
| Q3 2015 | $854,000 | +18.0% | 9,240 | +25.7% | 0.40% | +27.7% |
| Q2 2015 | $724,000 | -2.2% | 7,350 | -0.3% | 0.31% | +3.3% |
| Q1 2015 | $740,000 | +7.1% | 7,375 | -1.3% | 0.30% | +28.8% |
| Q4 2014 | $691,000 | – | 7,475 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brown Capital Management | 2,119,107 | $256,179,000 | 3.12% |
| STONE RUN CAPITAL, LLC | 42,925 | $5,189,000 | 2.67% |
| 440 INVESTMENT GROUP, LLC | 27,820 | $3,363,000 | 2.56% |
| Summit Creek Advisors LLC | 106,517 | $12,877,000 | 2.54% |
| MAIRS & POWER INC | 1,444,480 | $174,623,000 | 2.10% |
| QUANTUM CAPITAL MANAGEMENT | 57,094 | $6,902,000 | 1.63% |
| Select Equity Group, L.P. | 1,709,914 | $206,711,503,000 | 1.57% |
| FRIESS ASSOCIATES LLC | 144,610 | $17,482,000 | 1.53% |
| Tygh Capital Management, Inc. | 61,813 | $7,473,000 | 1.49% |
| First Light Asset Management, LLC | 38,654 | $4,673,000 | 1.48% |